INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MiNK Therapeutics, Inc. (INKT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (C). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | B- (3.0) | C (2.4) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-11-05 | C+ (2.5) | C (2.5) | C (2.4) | B- (3.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-29 | C+ (2.5) | C (2.5) | C (2.3) | C+ (2.8) | C+ (2.7) | C+ (2.6) |
| 2026-10-22 | C+ (2.5) | C- (2.0) | C (2.3) | C+ (2.8) | C+ (2.6) | C (2.5) |
| 2026-10-15 | C+ (2.5) | C- (2.0) | C (2.3) | C (2.5) | C+ (2.6) | C (2.4) |